Difference between revisions of "Cirrhosis"

From Aging Chart
Jump to: navigation, search
(Autoloading by CXLParser)
(Autoloading by CXLParser)
 
Line 180: Line 180:
 
(.//.)<html><!--Pop-up for: Obstruction of bile !Pop-up-->
 
(.//.)<html><!--Pop-up for: Obstruction of bile !Pop-up-->
 
<div class="1J1S8RQTX-7BV609-8V9" style="display:none;">
 
<div class="1J1S8RQTX-7BV609-8V9" style="display:none;">
 +
  
  
Line 191: Line 192:
 
</div>(...)<!--Pop-up for: Hepatocyte destruction !Pop-up-->
 
</div>(...)<!--Pop-up for: Hepatocyte destruction !Pop-up-->
 
<div class="1J1S8KST8-1SDCZ2P-8S4" style="display:none;">
 
<div class="1J1S8KST8-1SDCZ2P-8S4" style="display:none;">
 +
  
  
Line 202: Line 204:
 
</div>(...)<!--Pop-up for: Liver stones  (crystals of cholesterol,  Bilirubin, salt and lime) !Pop-up-->
 
</div>(...)<!--Pop-up for: Liver stones  (crystals of cholesterol,  Bilirubin, salt and lime) !Pop-up-->
 
<div class="1J1S8WGJL-25RTJGV-8XF" style="display:none;">
 
<div class="1J1S8WGJL-25RTJGV-8XF" style="display:none;">
 +
  
  
Line 213: Line 216:
 
</div>(...)<!--Pop-up for: Bilirubin in blood !Pop-up-->
 
</div>(...)<!--Pop-up for: Bilirubin in blood !Pop-up-->
 
<div class="1J1SCLGXH-1SXT3JF-BPB" style="display:none;">
 
<div class="1J1SCLGXH-1SXT3JF-BPB" style="display:none;">
 +
  
  
Line 224: Line 228:
 
</div>(...)<!--Pop-up for: Cirrhosis !Pop-up-->
 
</div>(...)<!--Pop-up for: Cirrhosis !Pop-up-->
 
<div class="1J1S93R41-1WDGXHB-90L" style="display:none;">
 
<div class="1J1S93R41-1WDGXHB-90L" style="display:none;">
 +
  
  
Line 235: Line 240:
 
</div>(...)<!--Pop-up for: Cholesterol in blood !Pop-up-->
 
</div>(...)<!--Pop-up for: Cholesterol in blood !Pop-up-->
 
<div class="1N9Z04M7W-FGQVH3-26J9" style="display:none;">
 
<div class="1N9Z04M7W-FGQVH3-26J9" style="display:none;">
 +
  
  
Line 246: Line 252:
 
</div>(...)<!--Pop-up for: Abnormal liver function !Pop-up-->
 
</div>(...)<!--Pop-up for: Abnormal liver function !Pop-up-->
 
<div class="1J1S9C4GF-NZVMGM-99B" style="display:none;">
 
<div class="1J1S9C4GF-NZVMGM-99B" style="display:none;">
 +
  
  
Line 257: Line 264:
 
</div>(...)<!--Pop-up for: Lipophanerosis !Pop-up-->
 
</div>(...)<!--Pop-up for: Lipophanerosis !Pop-up-->
 
<div class="1J1S9GDGG-26THW9C-9JS" style="display:none;">
 
<div class="1J1S9GDGG-26THW9C-9JS" style="display:none;">
 +
  
  
Line 268: Line 276:
 
</div>(...)<!--Pop-up for: Impaired blood flow to liver !Pop-up-->
 
</div>(...)<!--Pop-up for: Impaired blood flow to liver !Pop-up-->
 
<div class="1J1S8SYTT-YGDR7G-8WB" style="display:none;">
 
<div class="1J1S8SYTT-YGDR7G-8WB" style="display:none;">
 +
  
  
Line 279: Line 288:
 
</div>(...)<!--Pop-up for: Impaired plasma  Composition !Pop-up-->
 
</div>(...)<!--Pop-up for: Impaired plasma  Composition !Pop-up-->
 
<div class="1J1S9D22J-VL7VSK-9CK" style="display:none;">
 
<div class="1J1S9D22J-VL7VSK-9CK" style="display:none;">
 +
  
  
Line 290: Line 300:
 
</div>(...)<!--Pop-up for: Obesity !Pop-up-->
 
</div>(...)<!--Pop-up for: Obesity !Pop-up-->
 
<div class="1J1S938FD-2BWHZ4G-8ZY" style="display:none;">
 
<div class="1J1S938FD-2BWHZ4G-8ZY" style="display:none;">
 +
  
  
Line 301: Line 312:
 
</div>(...)<!--Pop-up for: Medications !Pop-up-->
 
</div>(...)<!--Pop-up for: Medications !Pop-up-->
 
<div class="1J1S8K2H7-1C07FLK-8RN" style="display:none;">
 
<div class="1J1S8K2H7-1C07FLK-8RN" style="display:none;">
 +
  
  
Line 312: Line 324:
 
</div>(...)<!--Pop-up for: Portal hypertension !Pop-up-->
 
</div>(...)<!--Pop-up for: Portal hypertension !Pop-up-->
 
<div class="1J1S8NF4Y-NZ3VHB-8TF" style="display:none;">
 
<div class="1J1S8NF4Y-NZ3VHB-8TF" style="display:none;">
 +
  
  
Line 323: Line 336:
 
</div>(...)<!--Pop-up for: Splenomegaly !Pop-up-->
 
</div>(...)<!--Pop-up for: Splenomegaly !Pop-up-->
 
<div class="1J1S9DLH2-DYB8GZ-9FH" style="display:none;">
 
<div class="1J1S9DLH2-DYB8GZ-9FH" style="display:none;">
 +
  
  
Line 334: Line 348:
 
</div>(...)<!--Pop-up for: Malnutrition !Pop-up-->
 
</div>(...)<!--Pop-up for: Malnutrition !Pop-up-->
 
<div class="1J1S8JHNT-1C71F5F-8QM" style="display:none;">
 
<div class="1J1S8JHNT-1C71F5F-8QM" style="display:none;">
 +
  
  
Line 345: Line 360:
 
</div>(...)<!--Pop-up for: Infections !Pop-up-->
 
</div>(...)<!--Pop-up for: Infections !Pop-up-->
 
<div class="1J1S8JVLJ-5Y76JV-8R6" style="display:none;">
 
<div class="1J1S8JVLJ-5Y76JV-8R6" style="display:none;">
 +
  
  
Line 356: Line 372:
 
</div>(...)<!--Pop-up for: Alcohol abuse !Pop-up-->
 
</div>(...)<!--Pop-up for: Alcohol abuse !Pop-up-->
 
<div class="1J1S8H46S-15HH9H5-8PM" style="display:none;">
 
<div class="1J1S8H46S-15HH9H5-8PM" style="display:none;">
 +
  
  
Line 367: Line 384:
 
</div>(...)<!--Pop-up for: Chronic interstitial fibrosis and scarring !Pop-up-->
 
</div>(...)<!--Pop-up for: Chronic interstitial fibrosis and scarring !Pop-up-->
 
<div class="1J1S8F7BP-2CHNMLP-8NL" style="display:none;">
 
<div class="1J1S8F7BP-2CHNMLP-8NL" style="display:none;">
 +
  
  
Line 378: Line 396:
 
</div>(...)<!--Pop-up for: Anemia !Pop-up-->
 
</div>(...)<!--Pop-up for: Anemia !Pop-up-->
 
<div class="1J1S9CV08-P242R0-9BT" style="display:none;">
 
<div class="1J1S9CV08-P242R0-9BT" style="display:none;">
 +
  
  

Latest revision as of 09:26, 2 August 2015

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Cirrhosis

Cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, which leads to portal hypertension and end-stage liver disease. Fibrosis describes encapsulation or replacement of injured tissue by a collagenous scar. Liver fibrosis results from the perpetuation of the normal wound-healing response, resulting in an abnormal continuation of fibrogenesis (connective tissue production and deposition). Fibrosis progresses at variable rates depending on the cause of liver disease, environmental factors, and host factors.1–3 Cirrhosis is an advanced stage of liver fibrosis that is accompanied by distortion of the hepatic vasculature. The resultant vascular distortion leads to shunting of the portal and arterial blood supply directly into the hepatic outflow (central veins), compromising exchange between hepatic sinusoids and the adjacent liver parenchyma. The general circulatory abnormalities in cirrhosis (splanchnic vasodilation, vasoconstriction and hypoperfusion of kidneys, water and salt retention, increased cardiac output) are intimately linked to the hepatic vascular alterations and resulting portal hypertension. Cirrhosis and its associated vascular distortion are traditionally regarded as irreversible but recent data suggest that cirrhosis regression or even reversal is possible.

Nonalcoholic fatty liver disease (NAFLD) is hepatic steatosis associated with metabolic abnormalities such as overweight/central obesity, insulin resistance, type 2 diabetes (T2D), and dyslipidemia. NAFLD is becoming the most common liver disease in contemporary society, with the highest prevalence in those over 60 years. NAFLD pathology ranges from simple steatosis to a necroinflammatory fibrosing disorder called steatohepatitis (SH), the latter associated with high risk of developing cirrhosis, often occuring in the seventh to ninth decades of life. While the main health implications of NAFLD are increased risk of developing T2D, cardiovascular diseases, and common cancers, there is substantantially increased standardized mortality, and deaths from decompensated cirrhosis and hepatocellular carcinoma (HCC).